

FORTIS HEALTHCARE (INDIA) LIMITED
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011

(₹ in lacs)

Particulars	Consolidated			Standalone		
	Quarter Ended June 30		Year Ended March 31	Quarter Ended June 30		Year Ended March 31
	2011	2010	2011	2011	2010	2011
	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Audited)
1. Income from Operations	47,834	33,459	146,747	6,550	5,933	24,829
2. Other Operating Income	498	333	1,553	272	222	998
3. Total Income	48,332	33,792	148,300	6,822	6,155	25,827
4. Expenditure						
(a) Material Consumed	13,126	9,351	39,299	2,080	1,714	7,092
(b) Employees cost	9,190	6,273	27,312	1,658	1,202	5,852
(c) Net Depreciation & Amortization	3,450	2,152	10,449	281	267	1,040
(d) Legal & Professional Fees	692	560	15,025	392	244	1,103
(e) Professional Charges to Doctors	6,291	3,830	17,341	478	304	1,484
(f) Other expenditure	12,856	9,023	44,629	2,511	1,787	7,956
(g) Total	45,605	31,189	154,055	7,398	5,518	24,527
5. Profit (+)/ Loss (-) from Operations before Other income & interest (3-4)	2,727	2,603	(5,755)	(576)	637	1,300
6. Other Income	2,088	3,376	45,907	2,677	4,269	18,246
7. Profit (+)/ Loss (-) from Operations before Interest (5-6)	4,815	5,979	40,152	2,101	4,906	19,546
8. Interest (including finance charges)	3,013	7,103	24,999	927	2,142	5,365
9. Profit (+)/ Loss (-) from Ordinary activities before tax (7-8)	1,802	(1,124)	15,153	1,174	2,764	14,181
10. Tax expense	426	217	1,524	-	-	-
11. Net Profit/ Loss (9-10)	1,376	(1,341)	13,629	1,174	2,764	14,181
12. Less : Minority Interest in profit / (loss)	(18)	101	442	-	-	-
13. Add : Share in profit/(loss) of associate companies	9	11	(751)	-	-	-
14. Net Profit / (Loss) attributable to the shareholders of the Company	1,403	(1,431)	12,436	1,174	2,764	14,181
15. Paid-up equity share capital (Face Value ₹10 per Share)	40,512	40,506	40,510	40,512	40,506	40,510
16. Reserves excluding Revaluation Reserves			251,740			260,973
17. Earnings Per Share :- Basic	0.35	(0.44)	3.23	0.29	0.85	3.68
:- Diluted	0.35	(0.44)	3.23	0.29	0.85	3.68
18. Public shareholding - No of Shares	74,963,386	74,903,246	74,949,526	74,963,386	74,903,246	74,949,526
- Percentage of shareholding	18.5%	18.5%	18.5%	18.5%	18.5%	18.5%
19. Promoters and promoter group Shareholding						
a) Pledged/ Encumbered - No of Shares	150,045,500	115,340,500	150,045,500	150,045,500	115,340,500	150,045,500
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	45.4%	34.9%	45.4%	45.4%	34.9%	45.4%
- Percentage of shares (as a % of the total share capital of the company)	37.0%	28.5%	37.0%	37.0%	28.5%	37.0%
b) Non-encumbered - No of Shares	180,108,449	214,813,449	180,108,449	180,108,449	214,813,449	180,108,449
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	54.6%	65.1%	54.6%	54.6%	65.1%	54.6%
- Percentage of shares (as a % of the total share capital of the company)	44.5%	53.0%	44.5%	44.5%	53.0%	44.5%

Notes:

- The financial results for the quarter ended June 30, 2011 have been reviewed by the Audit, Risk & Controls Committee and approved by the Board of Directors at their respective meetings held on August 12, 2011.
- The Group is primarily engaged in the business of healthcare services, which as per Accounting Standard 17 on 'Segment Reporting' issued by the ICAI is considered to be the only reportable business segment. The Group's principal operating locations are based in India which is considered as a single

amur

geographical segment. Further, the business of Super Religare Laboratories Limited (and its subsidiary and joint ventures, more fully explained in note 8(b) below) is provision of diagnostic services and is considered as same business segment of healthcare services.

3. Other income includes interest income, unclaimed balances and excess provisions written back, foreign exchange fluctuation gain, profit on sale of assets, profit on sale of investment and miscellaneous income, whichever is relevant for the period/year.
4. Due to restatement and settlement of foreign currency monetary items, the Company and its subsidiaries recognize foreign exchange fluctuation differences in the profit and loss account. This difference may result in either net gain or loss and is accordingly, included under 'other income' or 'other expenditure' for the specific period.
5. The statutory auditors have reported their inability to express an opinion on the matter relating to land under leasehold arrangements with the Delhi Development Authority and certain demands raised by the income tax authorities in respect of a subsidiary aggregating to ₹ 9,509 lacs. As the matters are sub-judice, and appeals against the demands are pending at various stages and based on the advice received from legal counsels, the management is of the view that the matters shall get resolved in its favor. Further, the statutory auditors have reported, in case of a newly acquired subsidiary, their inability to express an opinion on the matter relating to the manual adjustments of certain assets and liabilities in the accounting system and unexplained items aggregating ₹ 250 lacs in certain bank reconciliation statements in respect of a subsidiary. Based on its assessment, the management is of the view that such manual adjustments and unexplained items in bank reconciliation statements would not have any material effect on the consolidated profits of the Group as these are primarily arising out of migration of old accounting system to a new ERP based system.
6. Number of Investors Complaints received and disposed off during the quarter ended June 30, 2011: (i) Pending at the beginning of the quarter – Nil. (ii) Received during the quarter – 2. (iii) Disposed of during the quarter – 2 (iv) Lying unresolved at the end of the quarter – Nil.
7. On April 12, 2011, the Company has allotted 13,860 Equity Shares of ₹ 10/- each, out of which 11,860 shares have been allotted at a premium of ₹ 61/- per share and 2,000 shares have been allotted at a premium of ₹ 67/- per share, to the eligible employees, upon exercise of vested stock options, under the 'Employee Stock Option Plan 2007' of the Company. Accordingly, the Paid up equity share capital of the Company has been increased from ₹ 40,510.35 lacs to ₹ 40,511.73 lacs.
8. a) During the quarter, the Company has acquired remaining 10% stake in Escorts Heart Institute and Research Centre Limited ('EHIRCL') on April 27, 2011, for ₹ 13,000 lacs from Fortis Healthcare Holdings Limited, resulting in EHIRCL (together with its two wholly owned subsidiaries) becoming wholly owned subsidiary of the Company. ₹ 64.31 lacs of net profits attributable to shareholders has arisen from this acquisition.

b) During the quarter, the Company has acquired 74.59% stake in Super Religare Laboratories Limited ('SRL') on May 12, 2011, for ₹ 80,368.53 lacs, resulting in SRL (together with its wholly owned subsidiary and two joint ventures) becoming subsidiary of the Company. SRL has one subsidiary and two joint ventures. ₹ 6,209.61 lacs included in revenue and ₹ 122.68 lacs of net loss attributable to shareholders has arisen from this acquisition.

c) During the quarter, the Group incorporated Fortis Health Management (North) Limited, Fortis Health Management (East) Limited, Fortis Health Management (West) Limited and Fortis Health Management (South) Limited as wholly owned subsidiaries.
9. During the quarter, with a view to streamline and focus on Group's resources and energies on the divisions and undertakings pertaining to provision of hospital infrastructure, out patient consultation services, daycare services, radiology, imaging, diagnostic services and as a matter of strategic business opportunity, the Group has decided to sell and transfer the business undertaking of some of its subsidiaries comprising of a) hospital Operation & Management; b) In-patient healthcare services; and c) emergency healthcare services, on a going concern basis by way of a slump sale in favor of any of its Subsidiary Company/its Affiliates/Group Company/Companies under the same management/ other body corporate.


annex

As part of this plan, some of the subsidiaries of the Group have sold the business undertaking comprising of a) hospital Operation & Management; b) In-patient healthcare services; and c) emergency healthcare services to newly incorporated subsidiary, Fortis Health Management (North) Limited. Adjustments, if any, to carrying value of assets, goodwill, liabilities, recoverability of MAT and related tax impact would be ascertained on completion of restructuring.

10. The previous periods figures have been regrouped and recasted, wherever considered necessary.

Date: August 12, 2011
Place: New Delhi

for and on behalf of the Board of Directors


Shivinder Mohan Singh
Managing Director



Read. Office: Escorts Heart Institute & Research Centre, Okhla Road, New Delhi – 110 025